MeiraGTx Hldgs (NASDAQ:MGTX) Bolsa

MeiraGTx Hldgs

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

MeiraGTx Holdings PLC

USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) (USAR or the Company), today announced that it has entered into a securities purchase agreement with a new fundamental institutional investor to raise $75 million of equity capital via a private investment in public equity ("PIPE"). The Company intends to use the proceeds from the offering to fund capital expenditures for its magnet manufacturing facility in Stillwater, Oklahoma, as well as for working capital and operating expenses.
Under the terms of the securities purchase agreement, the Company will issue, for an aggregate purchase price of $75 million, an aggregate of approximately 8.55 million shares of common stock (the Issued Shares), pre-funded warrants to purchase an aggregate of approximately 2.16 million shares of common stock (the shares underlying the Pre-Funded Warrants, together with the Issued Shares, "the Aggregate Shares") and warrants (the PIPE Warrants) to purchase shares of common stock, in an amount equal to 100% of the Aggregate Shares at a strike price of $7.00 per share, with an expiry date of 6-years from the issue date of the PIPE Warrants. The Shares and the PIPE Warrant Shares are entitled to customary resale registration rights.
 &nbsp;

News

USAR

USA Rare Earth Enters Into Securities Purchase Agreement With New Fundamental Institutional Investor To Raise $75M Of Equity Capital Via PIPE

TLRY

Tilray Brands' 10 Barrel Brewing Unveils NA Apocalypse IPA, Offering Bold, Hop-Driven Flavor Without The Alcohol

Earnings

ETSY

Etsy Q1 2025 Adj. EPS $0.46 Misses $0.49 Estimate, Sales $651.18M Beat $642.67M Estimate

Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.17 by 23.53 percent. This is a 51.85 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $2.35 billion which beat the analyst consensus estimate of $2.30 billion by 2.33 percent. This is a 14.00 percent decrease over sales of $2.73 billion the same period last year.

Earnings Beats

Earnings Misses

Dana Q1 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $2.35B Beat $2.30B Estimate

Leerink Partners analyst Puneet Souda downgrades NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) from Outperform to Market Perform and lowers the price target from $25 to $9.

Downgrades

Price Target

Analyst Ratings

Leerink Partners Downgrades NeoGenomics to Market Perform, Lowers Price Target to $9

HC Wainwright &amp; Co. analyst Yi Chen reiterates LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) with a Buy and maintains $14 price target.

Reiteration

LFMD

HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $14 Price Target

Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) affirms FY2025 Adj EPS guidance from $4.40-$4.60 to $4.40-$4.60 vs $4.49 analyst estimate..

Guidance

Spire Affirms FY2025 Adj EPS Guidance of $4.40-$4.60 vs $4.49 Est

<ul>
<li>Amylyx expects completion of recruitment for the LUCIDITY trial in 2025, with topline data in first half of 2026</li>
<li>Pivotal Phase 3 LUCIDITY trial evaluating avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation and Orphan Drug Designation; FDA-agreed-upon primary outcome of reduction in hypoglycemic events</li>
<li>Avexitide has been previously evaluated in five post-bariatric hypoglycemia (PBH) clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant reductions in hypoglycemic events</li>
<li>The Company continues to expect cash runway through the end of 2026</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54246224&amp;newsitemid=20250429337166&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=4a42d2ccab20c0ba32567d801f80a9bc">Amylyx Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) ("Amylyx" or the "Company") today announced that the first participant has been dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH).

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharma Announces First Participant Dosed In Pivotal Phase 3 LUCIDITY Clinical Trial Of Avexitide For Treatment Of Post-bariatric Hypoglycemia

XPRO

Expro Group Holdings Says 'Consistent with our fourth quarter earnings call, our view remains that we will continue to make progress in 2025 toward our medium-term target of mid-20s Adjusted EBITDA margin, notwithstanding near-term uncertainty related to tariffs, additional OPEC+ supply, and a range of geopolitical risks'

<ul>
<li>Statistically significant efficacy in biomarker subgroup analyses was observed:</li>
<li>&nbsp;
<ul>
<li>78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup</li>
<li>61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase (MPO) subgroup</li>
<li>90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score (CPS) subgroup</li>
</ul>
</li>
<li>The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study</li>
</ul>

PPBT

Purple Biotech's CM24 Shows Up To 90% Reduction In Death Risk In Pancreatic Cancer Patients, Biomarker Insights To Drive Next Phase 2b Study

Stock Split

LITM

Snow Lake Resources Announces 1-for-13 Reverse Stock Split, Will Become Effective May 2

Martin Marietta Sees FY25 Revenue Of $6.830B - $7.230B Vs. $7.021B Est.

Expro Gr Hldgs Sees Q2 Sales $400.000M-$410.000M vs $430.43M Est

Shenandoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHEN#NASDAQ">SHEN</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 137.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $87.90 million which missed the analyst consensus estimate of $89.31 million by 1.58 percent. This is a 26.93 percent increase over sales of $69.25 million the same period last year.

SHEN

Shenandoah Q1 EPS $(0.19) Misses $(0.14) Estimate, Sales $87.90M Miss $89.31M Estimate

Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will acquire Regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. The upfront cash portion of the consideration represents a premium of 274 percent to Regulus' 60-day volume-weighted average stock price and 108 percent to Regulus' closing price on April 29, 2025. In addition, Regulus shareholders will receive a contingent value right (CVR) providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus' lead product candidate, farabursen. Total consideration including the CVR, if the milestone is achieved, would be approximately $1.7 billion. The transaction has been unanimously approved by the Boards of Directors of both companies.
Completion of the transaction is expected in the second half of 2025, subject to the satisfaction or waiver of customary closing conditions, including the tender of shares representing at least a majority of the total number of Regulus' outstanding shares, and other customary closing conditions and regulatory clearance. Until that time, Regulus will continue to operate as a separate and independent company.
&nbsp;

RGLS

Novartis To Buy Regulus Therapeutics For $7.00/Shr In Cash, With Potential To Receive Addl $7.00/Shr In Cash Through Contingent Value Right, For Total Equity Value Of Up To About $1.7B

Financing

USA Rare Earth Announces Enters Securities Purchase Agreement With Institutional Investor To Raise $75M Via PIPE

The chief economic adviser to President Donald Trump, Stephen Miran, reportedly struggled to reassure major bond and hedge fund investors during a meeting last week.
What Happened: Miran, who also heads the Council of Economic Advisers, met with representatives from top hedge funds and other significant investors at the White House on Friday. The meeting was organized amid a period of heightened market instability caused by Trump&#8217;s tariff policies, according to a <a href="https://www.ft.com/content/a815323b-ae2b-4586-aec2-39dec35726f0">Financial Times</a> report. The meeting, arranged by Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), included representatives from hedge funds Balyasny, Tudor and Kenneth Griffin&#8216;s Citadel, as well as asset managers PGIM and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>).
Several attendees expressed dissatisfaction with the meeting, describing Miran&#8217;s remarks on tariffs and markets as unclear or insufficient. Some even suggested that Miran was not up to the task. Some called him "incoherent"  while some said, he was &#8220;Out of his depth&#8221;. 
"When you're with an audience that knows a lot, the talking points are taken apart pretty quickly,&#8221; a source told Financial Times. 
However, one individual familiar with the meeting expressed optimism about the administration&#8217;s approach to deregulation and tax cuts. 
Earlier this month in a speech at the Hudson Institute, Miran proposed that countries either accept U.S. tariffs on their exports without retaliating or "write cheques to Treasury that help us finance global public goods" as potential solutions.
SEE ALSO: <a href="https://benzinga.com/news/25/04/45084963/joe-rogan-says-people-dont-realize-how-quickly-things-can-collapse-just-how-los-angeles-fell-apart-the-us-co" target="_blank" rel="noreferrer noopener">Joe Rogan Says People Don&#8217;t Realize How Quickly Things Can Collapse: &#8216;Just How Los Angeles Fell Apart The US Could Fall Apart Too&#8217;</a>
Why It Matters: The Trump administration&#8217;s policies have led to significant fluctuations in U.S. equity and debt markets. U.S. government bonds experienced a sharp sell-off following the president&#8217;s announcement of steep tariffs on April 2.
Recently, hedge fund manager Spencer Hakimian <a href="https://www.benzinga.com/markets/25/04/45031287/us-companies-earn-6x-more-in-china-than-they-export-heres-why-blowing-up-global-trade-would-be-economic-suicidesays-leading-fund-manager">criticized the ongoing</a> trade and tariff war, describing it as unprecedentedly &#8220;stupid&#8221;. He highlighted that S&amp;P 500 companies generate nearly $1.17 trillion in annual revenue from China. Meanwhile, some investors have managed to <a href="https://www.benzinga.com/25/04/44893887/greenlight-capitals-gold-investments-yield-high-returns-amidst-market-downturn">find success</a> amid the market downturn. Billionaire investor David Einhorn&#8216;s hedge fund, Greenlight Capital, reported an 8.2% return in the first quarter of 2025, significantly outperforming the S&amp;P 500&#8217;s loss of over 4% during the same period.
However, according to most investors, declining long-term bond prices and a weakening dollar indicate that the U.S.&#8217;s status as a safe haven in global markets is facing pressure.
Vanguard Total Bond Market Index Fund ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BND#NASDAQ">BND</a>) climbed 2.24% year-to-date, while iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 3% during the same period. 
<ul>
<li>READ MORE: <a href="https://benzinga.com/news/25/04/45090231/elon-musk-says-will-come-as-a-surprise-to-most-as-chinas-economy-surpasses-us-and-eu-amid-rising-tariffs-and" target="_blank" rel="noreferrer noopener">Elon Musk Says Will Come As A &#8216;Surprise To Most&#8217; As China&#8217;s Economy Surpasses US And EU Amid Rising Tariffs And Growing Recession Fears</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

iShares Trust Barclays 20+ Year Treasury Bond Fund

Key Trump Adviser's Attempt To Reassure Investors Amid Market Turmoil Draws Criticism As Some Say He Was 'Out Of His Depth': 'When You're With An Audience That Knows A Lot...'

Wabash National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) is looking for FY2025 Adj EPS of $(0.85)-$(0.35) vs $0.72 analyst estimate. Lowers FY2025 sales outlook from $1.90 billion-$2.10 billion to $1.80 billion vs $1.87 billion estimate.

Wabash National Sees FY2025 Adj EPS $(0.85)-$(0.35) vs $0.72 Est; Lowers FY2025 Sales Guidance from $1.90B-$2.10B to $1.80B vs $1.87B Est

Expro Gr Hldgs Q1 Adj. EPS $0.25 Beats $0.11 Estimate, Sales $390.87M Beat $373.39M Estimate

Needham analyst Joshua Reilly reiterates AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) with a Buy and maintains $25 price target.

AEYE

Needham Reiterates Buy on AudioEye, Maintains $25 Price Target

Press Releases

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Health Care

General

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Contracts

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Comments

MeiraGTx Hldgs

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL